Lucas Wiegand, MD
Urology · Orlando, FLNPI 1083893101
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (37.9%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 61.9% of it on its own, with 36 other manufacturers making up the rest. Among urology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 355 payments — averaging $382.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$84K
- Endo USA, Inc.$24K
- Coloplast$8K
- Laborie Medical Technologies Corp.$7K
- Provepharm Inc.$4K
- Boston Scientific$4K
- plus $6K from 31 others
Across 53 payments — averaging $8526.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Provepharm Inc.$224K
- Endo Pharmaceuticals Inc.$117K
- Laborie Medical Technologies Corp.$91K
- Endo USA, Inc.$20K
What the payments were for
- Consulting fees$34,68026%
- Speaking & faculty fees$18,20013%
- Grants$2780%
- Travel & lodging$16,26512%
- Food & beverage$14,99311%
- Education$51,46238%
- Gifts$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 125 | $84,057 |
| Endo USA, Inc. | 14 | $23,808 |
| Coloplast | 65 | $7,923 |
| Laborie Medical Technologies Corp. | 11 | $6,571 |
| Provepharm Inc. | 2 | $3,750 |
| Boston Scientific | 44 | $3,552 |
| Axonics, Inc. | 13 | $1,088 |
| Histosonics, Inc. | 1 | $954 |
| Medtronic(2 entities) | 9 | $877 |
| Olympus America Inc. | 7 | $654 |
| Johnson & Johnson(2 entities) | 8 | $223 |
| Ferring Pharmaceuticals Inc. | 5 | $219 |
| Biotissue Holdings Inc. | 1 | $200 |
| Calyxo, Inc. | 3 | $196 |
| AbbVie(2 entities) | 9 | $194 |
| Endo Pharmaceuticals Inc. | 3 | $181 |
| Baxter Healthcare | 2 | $175 |
| Kerecis Limited | 1 | $150 |
| Teleflex LLC | 1 | $143 |
| Blue Earth Diagnostics | 3 | $142 |
| Photocure Inc | 1 | $108 |
| Procept Biorobotics Corporation | 2 | $102 |
| Myriad Genetic Laboratories, Inc. | 3 | $93 |
| Urogen Pharma, Inc. | 3 | $79 |
| Sumitomo Pharma America, Inc. | 3 | $79 |
| Dendreon Pharmaceuticals LLC | 2 | $58 |
| Progenics Pharmaceuticals, Inc. | 2 | $48 |
| Conmed Corporation | 2 | $40 |
| Guard Medical Inc. | 2 | $36 |
| BD | 1 | $32 |
| Janssen Scientific Affairs, LLC | 1 | $28 |
| Tolmar, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $24 |
| Pfizer | 1 | $24 |
| Organogenesis Inc. | 1 | $23 |
| Immunitybio, Inc. | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$72,756
- XIAFLEX$12,291
- DA VINCI SP$10,100
- Optilume Urethral Drug Coated Balloon$5,208
- BLUDIGO$3,750
- SPEEDICATH$3,352
- Luja Coude$2,569
- INTERSTIM$723
- Axonics$706
- Bulkamid$706
- Kerecis SurgiClose$598
- GENERAL - THERAPIES$575
- TITAN$529
- GENERAL KIDNEY STONE DISEASE$435
- iTIND System$403
- GENERAL ERECTILE DYSFUNCTION$397
- AMS 700$286
- Spectra$284
- AMS$251
- CVAC Aspiration System$150
How this compares
$135,887 in reported general payments places this provider in the 95th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 47 | $36,734 |
| Gentamicin Sulfate | 88 | $2,540 |
| Oxybutynin Chloride | 17 | $374 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 44 | $295 |
| Tamsulosin Hcl | 14 | $156 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 36 | $130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $24 | $36,73447 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 935 urology providers in Florida.
Other urology in Orlando
- Olubayo TojuolaOrlando$283K
- Jeffrey BradyOrlando$145K
- Christopher RussellOrlando$84K
- Albert OngOrlando$77K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.